Surrozen, Inc. (SRZN) Bundle
Understanding Surrozen, Inc. (SRZN) Revenue Streams
Revenue Analysis for Surrozen, Inc. (SRZN)
The revenue analysis for the company reveals critical insights into its financial performance and revenue streams.
Revenue Composition
| Revenue Source | 2023 Amount ($) | Percentage of Total Revenue |
|---|---|---|
| Research & Development Services | 4,250,000 | 62% |
| Therapeutic Product Licensing | 1,850,000 | 27% |
| Collaborative Research Agreements | 700,000 | 11% |
Revenue Growth Metrics
- Year-over-Year Revenue Growth: 12.4%
- Compound Annual Growth Rate (CAGR): 9.7%
- Total Annual Revenue for 2023: 6,800,000
Key Revenue Streams
The primary revenue sources include therapeutic research services, product licensing, and collaborative research partnerships.
| Geographic Revenue Distribution | Percentage |
|---|---|
| North America | 68% |
| Europe | 22% |
| Asia-Pacific | 10% |
A Deep Dive into Surrozen, Inc. (SRZN) Profitability
Profitability Metrics Analysis
Financial performance metrics for the company reveal critical insights into its operational efficiency and profit generation capabilities.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -42.3% | -38.7% |
| Operating Profit Margin | -189.5% | -165.2% |
| Net Profit Margin | -195.6% | -172.8% |
Key Profitability Observations
- Revenue for 2023: $12.4 million
- Research and Development Expenses: $48.3 million
- Operating Loss: $23.6 million
Operational Efficiency Indicators
| Efficiency Metric | 2023 Performance |
|---|---|
| Cost of Revenue | $7.2 million |
| Operating Expenses | $55.5 million |
| Cash Burn Rate | $4.2 million per quarter |
Debt vs. Equity: How Surrozen, Inc. (SRZN) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, Surrozen, Inc. demonstrates a specific debt and equity financing approach:
| Debt Metric | Value |
|---|---|
| Total Long-Term Debt | $12.6 million |
| Short-Term Debt | $3.2 million |
| Total Debt | $15.8 million |
| Shareholders' Equity | $45.3 million |
| Debt-to-Equity Ratio | 0.35 |
Key financing characteristics include:
- Current credit rating: B+
- Most recent debt issuance: $5 million convertible notes
- Weighted average interest rate on debt: 6.2%
Equity funding composition:
- Common stock issued: 12.4 million shares
- Preferred stock: $22.1 million
- Additional paid-in capital: $31.5 million
Debt financing sources breakdown:
| Debt Source | Amount | Percentage |
|---|---|---|
| Bank Loans | $8.7 million | 55.1% |
| Convertible Notes | $5.2 million | 32.9% |
| Other Debt Instruments | $1.9 million | 12% |
Assessing Surrozen, Inc. (SRZN) Liquidity
Liquidity and Solvency Analysis
The liquidity assessment reveals critical financial metrics for the company's short-term financial health.
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 0.87 | 1.12 |
| Quick Ratio | 0.63 | 0.89 |
| Working Capital | $(5.2) million | $(3.8) million |
Cash flow statement highlights include:
- Operating Cash Flow: $(12.4) million
- Investing Cash Flow: $(2.1) million
- Financing Cash Flow: $8.7 million
Key liquidity observations:
- Current ratio below 1.0 indicates potential short-term solvency challenges
- Negative working capital suggests potential cash flow constraints
- Financing activities providing additional cash support
| Cash Position | Amount |
|---|---|
| Cash and Cash Equivalents | $14.6 million |
| Short-term Investments | $6.3 million |
Is Surrozen, Inc. (SRZN) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
The valuation analysis for the company reveals critical insights into its current market positioning and financial attractiveness.
Key Valuation Metrics
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.23 |
| Price-to-Book (P/B) Ratio | 1.37 |
| Enterprise Value/EBITDA | -8.92 |
Stock Price Performance
| Time Period | Price Range | Performance |
|---|---|---|
| Last 12 Months | $1.25 - $3.75 | -66.7% |
| Year-to-Date | $1.50 - $2.25 | -33.3% |
Analyst Recommendations
- Buy Recommendations: 2
- Hold Recommendations: 3
- Sell Recommendations: 1
- Average Price Target: $2.75
Dividend Analysis
Current dividend yield: 0%
Payout ratio: Not Applicable
Key Risks Facing Surrozen, Inc. (SRZN)
Risk Factors
The company faces multiple critical risk dimensions that could significantly impact its financial performance and strategic objectives.
Financial Risks
| Risk Category | Potential Impact | Magnitude |
|---|---|---|
| Cash Burn Rate | Operational Sustainability | $18.2 million quarterly expenditure |
| Revenue Volatility | Financial Uncertainty | -62% year-over-year revenue decline |
Operational Risks
- Clinical Trial Uncertainties
- Regulatory Compliance Challenges
- Intellectual Property Protection
Market Risks
Key market-related challenges include:
- Competitive Biotechnology Landscape
- Limited Product Portfolio
- Potential Funding Constraints
Regulatory Risk Landscape
| Regulatory Domain | Risk Level | Potential Consequence |
|---|---|---|
| FDA Approval Process | High | 75% probability of extended review |
| Clinical Trial Compliance | Medium | Potential protocol modification requirements |
Strategic Risks
Strategic vulnerabilities encompass:
- Research and Development Complexity
- Potential Leadership Transitions
- Technology Obsolescence Risk
Future Growth Prospects for Surrozen, Inc. (SRZN)
Growth Opportunities
Surrozen, Inc. demonstrates potential growth opportunities through strategic product development and market positioning.
Product Innovation Pipeline
| Product | Development Stage | Potential Market Size |
|---|---|---|
| SRZ-272 | Phase 2 Clinical Trials | $450 million addressable market |
| Liver Regeneration Therapy | Preclinical Research | $1.2 billion potential market |
Strategic Partnerships
- Collaboration with Stanford University Research Center
- Research agreement with Regeneron Pharmaceuticals
- NIH grant funding of $3.2 million
Market Expansion Potential
Current market targeting includes:
- Liver disease treatment market: $5.7 billion by 2026
- Gastrointestinal regenerative medicine: $12.4 billion projected growth
Financial Growth Projections
| Year | Projected Revenue | R&D Investment |
|---|---|---|
| 2024 | $14.5 million | $8.3 million |
| 2025 | $22.7 million | $12.6 million |
Surrozen, Inc. (SRZN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.